Medsan to provide testing for RetinalGeniX study on personalizing wet AMD care
Click Here to Manage Email Alerts
RetinalGeniX has contracted with Medsan to provide diagnostic testing for a study on personalizing medical evaluations for patients with wet age-related macular degeneration.
“We are pleased to extend our services into testing for wet macular degeneration, a field that we have been looking at for quite some time,” Medsan CEO Jonathan Brenner, PhD, said in a RetinalGeniX press release. “We feel that RetinalGeniX is the right partner to start this venture with.”
Image: Adobe Stock
RetinalGeniX plans to launch a clinical study with 390 patients to validate the relative suitability of anti-VEGF ocular injections for patients seeking treatment for wet AMD, as well as pharmaceutical clinical studies that are part of its DNA/RNA GPS initiative.
The company is also developing a retinal home and remote monitoring system to aid in early detection and treatment of ocular diseases by noting initial physiological changes that may indicate future disease.
“Medsan is a next-generation diagnostic CLIA-approved laboratory services facility equipped with the most technically advanced diagnostic equipment in the pharmaco-genetic space,” Jerry Katzman, MD, chairman, president and CEO of RetinalGeniX, said in the release. “Jonathan Brenner, PhD, and his team are specialists running diagnostic panels and dovetails RetinalGeniX’s clinical agenda to clinical study requirements. It's a perfect match. We look forward to working with Medsan on this strategic venture.”
Read more about
Click Here to Manage Email Alerts